Included in the formulation
АТХ:A.05.B.A Preparations for the treatment of liver diseases
Pharmacodynamics:Hepatoprotectant of plant origin. The therapeutic effect is due to a complex of biologically active substances, the most important of which are isoflavonoids (formononetin, genistein, retuzin, maakiasin), pterocarpanes, monomeric and dimeric trans-stilbenes (resveratrol and piceatanol).
It has a hepatoprotective, choleretic effect, contributes to the normalization of the impaired histo-artectomy of the liver, reducing the number of necrotic hepatocytes; eliminates the protein and fatty degeneration of the liver parenchyma. Inhibits the reactions of LPO; improves the respiratory function of mitochondria; stabilizes the membrane with lysosomes and inhibits the release of necrosogenic hydrolases, including phospholipase A; stimulates the processes of oxidation and conjugation of xenobiotics, glucuronidation of bilirubin; increases the excretory function of the liver; reduces hyperfermentation (level of aminotransferases, lactate dehydrogenase, alkaline phosphatase).
With chronic hepatitis, suppressing the synthesis of collagen and glucosaminoglycans stimulated by lipid peroxidation products, restrains the formation of fibrosis inside the hepatic lobules, providing anti-necrotic and anti-inflammatory action.
Has a choleretic effect: increases the rate of bile secretion and excretion of fatty acids, bilirubin and cholesterol into it.
Pharmacokinetics:Not studied.
Indications:At adults at treatment of an acute and chronic hepatitis, a cirrhosis of a liver, a fatty hepatosis, at a syndrome of a cholestasis.
I.B15-B19.B17.1 Acute hepatitis C
I.B15-B19.B16 Acute hepatitis B
I.B15-B19.B18.2 Chronic viral hepatitis C
I.B15-B19.B18 Chronic viral hepatitis
I.B15-B19.B15 Acute hepatitis A
XI.K70-K77.K73.9 Chronic hepatitis, unspecified
XI.K70-K77.K74 Fibrosis and cirrhosis of the liver
XI.K70-K77.K71 Toxic liver disease
XI.K70-K77.K70 Alcoholic liver disease
XI.K80-K87.K83.1 Blockage of the bile duct
Contraindications:Hypersensitivity, cholelithiasis (exacerbation period), pregnancy, lactation, age under 18.
Pregnancy and lactation:Contraindicated during pregnancy, during lactation.
The action category for fetus by FDA is N.
Dosing and Administration:Inside 1 tablet 3 times / day for 30-40 minutes before meals. Duration of treatment - 4 weeks. An increase in the duration and conduct of repeated courses of treatment is possible on the recommendation of a doctor.
Side effects:Allergic reactions.
Overdose:So far, no cases of overdose have been reported.
Interaction:Interaction with other drugs is not described.
Special instructions:Does not affect the ability to drive vehicles and engage in other potentially hazardous activities that require increased concentration and speed of psychomotor reactions.